JP2016517883A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517883A5
JP2016517883A5 JP2016511718A JP2016511718A JP2016517883A5 JP 2016517883 A5 JP2016517883 A5 JP 2016517883A5 JP 2016511718 A JP2016511718 A JP 2016511718A JP 2016511718 A JP2016511718 A JP 2016511718A JP 2016517883 A5 JP2016517883 A5 JP 2016517883A5
Authority
JP
Japan
Prior art keywords
item
pharmaceutical composition
composition according
subject
sovetirom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016511718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053640 external-priority patent/WO2014178892A1/en
Publication of JP2016517883A publication Critical patent/JP2016517883A/ja
Publication of JP2016517883A5 publication Critical patent/JP2016517883A5/ja
Withdrawn legal-status Critical Current

Links

JP2016511718A 2013-05-03 2013-08-05 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 Withdrawn JP2016517883A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
US61/819,467 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018137754A Division JP2018162321A (ja) 2013-05-03 2018-07-23 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Publications (2)

Publication Number Publication Date
JP2016517883A JP2016517883A (ja) 2016-06-20
JP2016517883A5 true JP2016517883A5 (OSRAM) 2016-09-23

Family

ID=51843844

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016511718A Withdrawn JP2016517883A (ja) 2013-05-03 2013-08-05 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2016511726A Active JP6360552B6 (ja) 2013-05-03 2014-02-05 髄鞘形成疾患の処置におけるソベチロム
JP2018118891A Pending JP2018141024A (ja) 2013-05-03 2018-06-22 髄鞘形成疾患の処置におけるソベチロム
JP2018137754A Pending JP2018162321A (ja) 2013-05-03 2018-07-23 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016511726A Active JP6360552B6 (ja) 2013-05-03 2014-02-05 髄鞘形成疾患の処置におけるソベチロム
JP2018118891A Pending JP2018141024A (ja) 2013-05-03 2018-06-22 髄鞘形成疾患の処置におけるソベチロム
JP2018137754A Pending JP2018162321A (ja) 2013-05-03 2018-07-23 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Country Status (12)

Country Link
US (3) US10226438B2 (OSRAM)
EP (1) EP2991670B8 (OSRAM)
JP (4) JP2016517883A (OSRAM)
CN (1) CN105431163A (OSRAM)
AU (1) AU2014260468A1 (OSRAM)
BR (1) BR112015027682A2 (OSRAM)
CA (1) CA2911309A1 (OSRAM)
ES (1) ES2745532T3 (OSRAM)
MX (2) MX379043B (OSRAM)
RU (1) RU2015151216A (OSRAM)
SG (2) SG10201709090UA (OSRAM)
WO (2) WO2014178892A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
ES2861594T3 (es) 2014-04-30 2021-10-06 Univ Johns Hopkins Composiciones de dendrímeros y su uso en el tratamiento de enfermedades del ojo
AU2015301575B2 (en) 2014-08-13 2018-05-10 The Johns Hopkins University Selective dendrimer delivery to brain tumors
JP7088473B2 (ja) * 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
KR102407059B1 (ko) 2016-04-22 2022-06-10 바이킹 테라퓨틱스 인코포레이티드 갑상선 베타-작용제의 사용
US20190134069A1 (en) * 2016-04-22 2019-05-09 Viking Therapeutics, Inc. Use of thyroid beta-agonists
HUE056357T2 (hu) * 2016-05-18 2022-02-28 Univ Oregon Health & Science Szobetirom származékok
WO2018032012A1 (en) 2016-08-12 2018-02-15 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
CA3061630C (en) 2017-04-27 2021-12-07 The Johns Hopkins University Dendrimer compositions for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
WO2019005816A1 (en) 2017-06-29 2019-01-03 Yale University COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING FIBROUS PULMONARY DISEASES
CN110891583B (zh) * 2017-07-18 2023-06-06 学校法人庆应义塾 针对Th1细胞诱导性细菌的抗菌组合物
EP3707193A1 (en) 2017-11-10 2020-09-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
AU2020232205A1 (en) 2019-03-01 2021-10-21 Autobahn Therapeutics, Inc. Novel thyromimetics
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス, インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
CA2240024A1 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
WO1998007435A1 (en) 1996-08-20 1998-02-26 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
PT1089968E (pt) 1998-06-30 2005-08-31 Univ California Analogos de hormona tiroideia e metodos para a sua preparacao
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CN1878545A (zh) * 2003-09-15 2006-12-13 奥德威研究院 甲状腺激素类似物及其使用方法
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
AU2005284879B2 (en) * 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
DK2187882T3 (da) 2007-07-11 2013-04-08 Medicinova Inc Behandling af progressiv neurodegenerativ sygdom med ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2010144943A1 (en) 2009-05-20 2010-12-23 Ozpharma Pty Ltd Buccal and/or sublingual therapeutic formulation
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA3115378A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
WO2014063720A1 (en) * 2012-10-25 2014-05-01 Renault Trucks Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Similar Documents

Publication Publication Date Title
JP2016517883A5 (OSRAM)
WO2015025228A3 (en) Compositions and therapeutic methods for accelerated plaque regression
JP2015528471A5 (OSRAM)
NZ707640A (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
JP2012193216A5 (OSRAM)
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
TN2012000458A1 (en) Uses of dgat1 inhibitors
BR112012029170A2 (pt) fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2012502047A5 (OSRAM)
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
IL291168B1 (en) Heteroarylamidopyridinol derivative and pharmaceutical preparation containing it as an active ingredient for the prevention or treatment of autoimmune disease
WO2015025226A3 (en) Compositions and therapeutic methods for accelerated plaque regression
JP2017505809A5 (OSRAM)
JP2014520856A5 (OSRAM)
MX2013002649A (es) Agente terapeutico contra el dolor.
BR112012021445A2 (pt) formulação farmacêutica ou neutracêutica.
EP4574150A3 (en) A magl inhibitor
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
CN110520135A (zh) 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途
JP2016069317A5 (ja) 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물